Coated stents for the prevention of restenosis: Part II

Circulation. 2002 Nov 26;106(22):2859-66. doi: 10.1161/01.cir.0000038984.30279.89.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Antineoplastic Agents / administration & dosage
  • Clinical Trials as Topic / statistics & numerical data
  • Coated Materials, Biocompatible / administration & dosage*
  • Coated Materials, Biocompatible / adverse effects
  • Coronary Artery Disease / surgery
  • Coronary Restenosis / etiology
  • Coronary Restenosis / prevention & control*
  • Coronary Vessels / drug effects
  • Coronary Vessels / surgery
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / adverse effects
  • Drug Implants / administration & dosage
  • Drug Implants / adverse effects
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects
  • Gold / administration & dosage
  • Gold / adverse effects
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Phosphorylcholine / administration & dosage
  • Secondary Prevention
  • Stents* / adverse effects
  • Stents* / standards
  • Stents* / trends
  • Steroids / administration & dosage
  • Steroids / adverse effects
  • Treatment Outcome

Substances

  • Anticoagulants
  • Antineoplastic Agents
  • Coated Materials, Biocompatible
  • Delayed-Action Preparations
  • Drug Implants
  • Enzyme Inhibitors
  • Immunosuppressive Agents
  • Steroids
  • Phosphorylcholine
  • Gold